Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 4 Mar 2019 |
| Orion Corporation: Managers' transactions - Satu Ahomäki | 4 Mar 2019 |
| Orion Corporation: Managers' transactions - Olli Huotari | 4 Mar 2019 |
| Orion Corporation: Managers' transactions - Virve Laitinen | 4 Mar 2019 |
| Orion Corporation: Managers' transactions - Christer Nordstedt | 4 Mar 2019 |